US 12115148 B1Patent grantUnited States

Thiazolidinedione Compound for Cancer Cell Screening

Official patent title

3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-5-(2-hydroxy-5-nitrobenzylidene)thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer

Arabic title: 3-(2-(1,3-ديوكسوإيزوإندولين-2-يل)إيثيل)-5-(2-هيدروكسي-5-نيتروبنزيليدين)ثيازوليدين-2,4-ديون بوصفه عاملًا محتملًا مضادًا للأورام ومحفزًا للاستموات

Invention

Problem

Cancer cells can evade normal programmed cell-death pathways, and continued research is needed to identify compounds that inhibit cancer-cell growth through defined apoptotic mechanisms.

Why it matters

New chemical leads can support preclinical oncology research, but activity observed in cultured cells does not establish safety or effectiveness in animals or patients.

Approach

The publication describes synthesis of a thiazolidinedione compound and its use in compositions that contact cancer-cell lines. It reports in-vitro growth inhibition and investigates apoptosis-related pathways including p53, BAX, caspases, BCL-2, MMP2, and MMP9.

Who may benefit

Potential beneficiaries are medicinal-chemistry groups, cancer-biology laboratories, pharmaceutical discovery teams, and researchers studying apoptosis; no patient benefit has been established.

Potential value

The technology links a defined synthetic route and compound identity with a documented panel of in-vitro cancer-cell assays, providing a starting point for further preclinical investigation rather than a validated therapy.

Background

Cancer involves uncontrolled cell growth and can be addressed through several treatment modalities, yet researchers continue to seek compounds that activate programmed cell death in malignant cells. Apoptosis is regulated by interacting pathways that include p53, BAX, caspases, and BCL-2-family proteins. The publication focuses on a thiazolidinedione derivative designed for cytotoxic contact with cultured cancer cells. Its reported evidence concerns chemical preparation and in-vitro assays, not animal studies, clinical trials, or approved treatment.

Technology overview

The compound is synthesized by reacting a substituted thiazolidine-2,4-dione with 2-hydroxy-5-nitrobenzaldehyde in a polar protic solvent, with acid and a heterocyclic amine, followed by reflux. The product is then evaluated in vitro against several human cancer-cell lines. The publication reports growth-inhibition and IC50 ranges and proposes apoptosis-related molecular pathways, while also describing possible carrier-based formulations within the reported laboratory study.

Potential applications

Preclinical research on apoptosis and cytotoxicity in cultured cancer-cell lines.
Medicinal-chemistry lead optimization around the disclosed thiazolidinedione scaffold.
Mechanistic studies of p53, BAX, caspase, BCL-2, MMP2, and MMP9 pathways.
Comparative in-vitro screening across lung, colorectal, prostate, pharyngeal, breast, and cervical cancer models.
Process-development studies for reproducible synthesis and purification of the compound.

Evidence-supported advantages

The publication provides a defined synthetic route for the identified compound.
In-vitro activity is reported across multiple human cancer-cell lines rather than one model alone.
The disclosure links growth inhibition with several apoptosis-related pathways for further study.
Reported IC50 and growth-inhibition ranges provide benchmarks for subsequent preclinical replication.
The claims cover both preparation of the compound and its use in cell-contact compositions.

Development stage

Chemical synthesis and in-vitro cancer-cell testing are documented; animal, clinical, regulatory, and commercial validation were not established.

Commercial opportunity

The compound may be considered for research licensing or a preclinical drug-discovery collaboration. Any development program would require independent assay replication, selectivity studies, pharmacology, toxicology, formulation, animal studies, regulatory review, and clinical trials; the publication does not establish therapeutic safety or efficacy.

Patent classifications

WIPO IPC

A61K31/427Preparations for medical, dental or toiletry purposes

CPC

A61K31/427Preparations for medical, dental or toiletry purposes

Inventors

First inventorTarek Ahmed Yousef
InventorSaad Shaaban
InventorAhmed A. Al-Karmalawy
InventorMarwa Sharaky

Keywords

thiazolidinedione
anticancer research
apoptosis
in-vitro cytotoxicity
cancer cell lines
IC50
medicinal chemistry
preclinical

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.